Psma-Hbed-Cc
Positron Emission Tomography
Telix Pharmaceuticals (Innovations) Pty LimitedradiopharmaceuticalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Positron Emission Tomography cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FCH National Taiwan University Hospital | Phase 4 | BB |
GADOPENTETATE DIMEGLUMINE National Taiwan University Hospital | Phase 4 | B |
DOTA-FAPI-04 GALLIUM GA-68 First Affiliated Hospital of Fujian Medical University | Early Phase 1 | C |
FLUDEOXYGLUCOSE University of California, Davis | Early Phase 1 | C |
DPA-714 University of California, Davis | Early Phase 1 | C |
CIMBI-36 University of Exeter | D | |
DASB University of Exeter | D |
Same molecule, other indications
Psma-Hbed-Cc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →